16. Crow-Fukase syndrome
12 clinical trials,   18 drugs   (DrugBank: 8 drugs),   5 drug target genes,   79 drug target pathways

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-003202-33-IT
(EUCTR)
15/09/200917/11/2009Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 POEMS SYNDROME
MedDRA version: 9.1;Level: SOC;Classification code 10029205
Trade Name: REVLIMID*21CPS 25MG
INN or Proposed INN: Lenalidomide
ISTITUTO CLINICO HUMANITASNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2NCT00971685
(ClinicalTrials.gov)
July 20093/9/2009The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasNULLRecruiting18 YearsN/ABoth16Phase 2Italy